Drug Profile
AZR MD 001
Alternative Names: AZR-MD-001Latest Information Update: 19 Dec 2023
Price :
$50
*
At a glance
- Originator Azura Ophthalmics
- Class Anti-inflammatories; Eye disorder therapies
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Meibomian gland dysfunction
- Phase II Dry eyes
Most Recent Events
- 18 Dec 2023 Efficacy and adverse events data from a phase II trial in Meibomian gland dysfunction released by Azura Ophthalmics
- 13 Oct 2023 Azura Ophthalmics completes a phase II trial in Meibomian gland dysfunction in Australia (Ophthalmic) (NCT05548491)
- 17 Nov 2022 Azura Ophthalmics plans a phase III pivotal trial in Meibomian gland dysfunction in 2023